Plaque psoriasis is a common disease that causes red, scaly, raised lesions on the skin, most commonly on the elbows, knees, scalp, and back. Psoriasis affects about 2% of the population and significantly decreases health-related quality of life, particularly if lesions are in areas that can affect daily functioning (e.g., the hands or soles of the feet) or affect social functioning (e.g., the face). Psoriasis is a chronic inflammatory condition that is associated with systemic diseases including psoriatic arthritis, other autoimmune diseases, the metabolic syndrome, and cardiovascular disease.
Interventions of interest:
- Adalimumab (Humira®, AbbVie)
- Etanercept (Enbrel®, Amgen, Inc.)
- Infliximab (Remicade®, Janssen)
Anti IL-17A agents:
- Secukinumab (Cosentyx®, Novartis)
- Ixekizumab (Taltz®, Eli Lilly and Co.)
- Brodalumab (SiliqTM,Valeant Pharmaceuticals and AstraZeneca)
Anti IL-12/13 agent:
- Ustekinumab (Stelara®, Janssen)
- Apremilast (Otezla®, Celgene)
The Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115
The New England CEPAC convened to deliberate and vote on evidence presented in ICER's report on treatments for psoriasis.
This report was open to public comment until October 20, 2016.
The public comment period on the Draft Evidence Report has closed.